OxSyBio
Develops droplet-based 3D bioprinting technology to produce synthetic tissue-like materials for regenerative medicine, wound healing, and drug delivery applications.
- CEO / Founder
- Hadrian Green
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $16.4M
- Latest Round
- Series A
- Key Investors
- Woodford Investment Management; IP Group; Parkwalk Advisors
Technology & Products
Key Products
3D bioprinted synthetic tissues for regenerative medicine, drug screening, and wound healing applications.
Technological Advantage
University of Oxford spin-out with foundational IP from Professor Hagan Bayley's lab; technology enables printing of functional synthetic tissues with potential for personalized treatments.
Differentiation
Value Proposition
Enables high-throughput, reproducible production of 3D printed tissues for disease modeling, drug screening, and potential organ repair, reducing reliance on donor organs and animal testing.
How They Differentiate
OxSyBio differentiates itself through its proprietary droplet-based inkjet bioprinting technology, which allows for high-throughput and reproducible production of synthetic tissue-like materials. This method offers greater precision and control compared to other bioprinting techniques, backed by its strong research ties to Oxford University.
Market & Competition
Target Customers
Medical research institutions, pharmaceutical companies, healthcare providers
Industry Verticals
Medical Research; Pharmaceuticals; Healthcare
Competitors
Organovo, CELLINK, Aspect Biosystems
Growth & Milestones
Growth Metrics
Annual revenue of £36.2M as of Dec 31, 2022; raised £10M in Series A financing in 2018; spun out from Oxford University in 2014 with £1M seed funding.
Major Milestones
Founded in 2014 as Oxford University spin-out; Raised £1M seed funding in 2014; Raised £10M Series A in 2018; Partnership with MRC Harwell in 2018